FDA Grants Orphan Drug Designation to X4 Pharmaceuticals' Mavorixafor for Congenital Treatment

26 Aug 2026 · 16:54 UTC

Observed price moves

XFOR+2.10%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next. We pay about $120,000 a month for the newswires behind this feed.